The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factorα

Inflammatory Bowel Diseases

Volumn 19, Issue 6, 2013, Pages 1224-1231

  Ueda, Naoyasu ^a   Tsukamoto, Hiroshi ^a   Mitoma, Hiroki ^b,c   Ayano, Masahiro ^a   Tanaka, Atsushi ^a   Ohta, Shun Ichiro ^a   Inoue, Yasushi ^a   Arinobu, Yojiro ^d   Niiro, Hiroaki ^a   Akashi, Koichi ^a   Horiuchi, Takahiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b SAGA UNIVERSITY   (Japan)

^c JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^d KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Apoptosis; Biologic therapies; Cytokines

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; GOLIMUMAB; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; APOPTOSIS; CASPASES; CELL MEMBRANE; CELL PROLIFERATION; COMPLEMENT SYSTEM PROTEINS; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; JURKAT CELLS; MUTATION; POLYETHYLENE GLYCOLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879206045     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e318280b169     Document Type: Article

References (28)

1. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol. 2001;19:163-196.
2. Rigby WF. Drug insight: different mechanisms of action of tumor necrosis factor antagonists?passive-aggressive behavior? Nat Clin Pract Rheumatol. 2007;3:227-233.
3. Ramos-Casals M, Brito-Zeron P, Munoz S, et al. BIOGEAS STUDY Group. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine. 2008;87:345-364.
4. Pennica D, Nedwin GE, Hayflick JS, et al. Human tumor necrosis factor: precursor structure, cDNA cloning, expression, and homology to lympho-toxin. Nature. 1984;312:724-729.
5. Kriegler M, Perez C, DeFay K, et al. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell. 1988;53:45-53.
6. Luettiq B, Decker T, Lohmann-Matthes ML. Evidence for the existence of two forms of membrane tumor necrosis factor: an integral protein and a molecule attached to its receptor. J Immunol. 1989;143:4034-4038.
7. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996;334:1717-1725.
8. Moss ML, Jin SL, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature. 1997;385:733-736.
9. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997;385: 729-733.
10. Vandenabeele P, Declercq W, Beyaert R, et al. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol. 1995;5: 392-399.
11. Horiuchi T, Mitoma H, Harashima S, et al. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford). 2010;49:1215-1228.
12. Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic effects of anti-TNF agents on transmembrane TNF-expressing cells: comparison among infliximab, etanercept and adalimumab. Arthritis Rheum. 2008;58:1248-1257.
13. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008; 117:244-279.
14. Mitoma H, Horiuchi T, Hatta N, et al. Infliximab induces potent antiinflammatory responses by outside-to-inside signals through transmembrane TNF-a. Gastroenterology. 2005;128:376-392.
15. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007;357:228-238.
16. Harashima S, Horiuchi T, Hatta N, et al. Outside-to-inside signal through the membrane TNF-α induces E-selectin (CD62E) expression on activated human CD4+ T cells. J Immunol. 2001;166:130-136.
17. Wilkinson RW, Lee-MacAry AE, Davies D, et al. Antibody-dependent cell-mediated cytotoxicity: a flow cytometry based assay using fluorophores. J Immunol Methods. 2001;258:183-191.
18. Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs. 2008;22:315-329.
19. Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des. 2004;10:1235-1244.
20. Vandenabeele P, Galluzzi L, Vanden Berghe T, et al. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol. 2010;11: 700-714.
21. Ivanov A, Beers SA, Walshe CA, et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest. 2009;119:2143-2159.
22. Sans M. Trying to reconcile genetic findings with resistance to lymphocyte apoptosis in Crohn's disease pathogenesis. Digestion. 2010;81:244-245.
23. Mudter J, Neurath MF. Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications. Gut. 2007;56:293-303.
24. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088-1094.
25. Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007;13:1323-1332.
26. Palframan R, Airey M, Moore A, et al. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods. 2009;31:36-41.
27. Shealy D, Cai A, Staquet K, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor a. MAbs. 2010;2:428-439.
28. Fiehn C, Vay S. Induction of inflammatory bowel disease flares by golimumab: report of three patients with enteropathic spondylarthritis or ankylosing spondylitis and comorbid colitis. Arthritis Rheum. 2011;63: 3640-3641.